Clinical Guidelines
Commentary & Perspectives

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • By

  • February 16, 2026

  • 9 min

Share

As precision medicine evolves, artificial intelligence (AI) is crucial for personalizing cancer treatment. AI enhances diagnostic accuracy, improves patient selection, and monitors therapy effectiveness by analyzing multi-layered biological data that traditional methods cannot capture. AstraZeneca emphasizes the need for multimodal biomarkers powered by AI to democratize patient access to personalized therapies. Collaboration across various sectors and regulatory clarity are needed to optimize diagnostic strategies, paving the way for better treatment outcomes tailored to individual patients.

Original Source(s)

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min

Related Content

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

Identifying HER2-low expression – A pathologist led slide review

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

  • December 14, 2022

Democratizing Tumor Genomic Profiling With Tailored Content

Join Us With Agilent For Our Webinar On Democratizing Tumor Genomic Profiling. The webinar will discuss the range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio and much, much more!

  • June 26, 2024